Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-214

Abstract

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma"

Keywords

• Nivolumab
• Ipilimumab
• Renal Cell